Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Construction in Progress (2018 - 2021)

Ascendis Pharma A's Construction in Progress history spans 4 years, with the latest figure at $2173.5 for Q4 2021.

  • For Q4 2021, Construction in Progress fell 20.74% year-over-year to $2173.5; the TTM value through Dec 2021 reached $2173.5, down 20.74%, while the annual FY2021 figure was $2248.5, 18.01% down from the prior year.
  • Construction in Progress for Q4 2021 was $2173.5 at Ascendis Pharma A, down from $2742.3 in the prior quarter.
  • Across five years, Construction in Progress topped out at $3.0 million in Q4 2019 and bottomed at $2173.5 in Q4 2021.
  • The 4-year median for Construction in Progress is $115510.8 (2018), against an average of $805448.0.
  • The largest annual shift saw Construction in Progress surged 1209.18% in 2019 before it crashed 99.91% in 2020.
  • A 4-year view of Construction in Progress shows it stood at $228279.3 in 2018, then soared by 1209.18% to $3.0 million in 2019, then plummeted by 99.91% to $2742.3 in 2020, then fell by 20.74% to $2173.5 in 2021.
  • Per Business Quant, the three most recent readings for ASND's Construction in Progress are $2173.5 (Q4 2021), $2742.3 (Q4 2020), and $3.0 million (Q4 2019).